ArticleNature. Mental health2025
Illuminating posterior targets for TMS beyond the prefrontal cortex.
Article in Nature. Mental health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Convergence of TMS Sites and Lesion Locations Associated With Nicotine Addiction Improvement on a Common Brain Circuit.The American journal of psychiatry · 2026Article
- Determinants of Repetitive Transcranial Magnetic Stimulation Efficacy in Tobacco Use Disorder: A Pre-Registered Study.medRxiv : the preprint server for health sciences · 2026Article
- Structural connectome architecture and biological vulnerability shape cortical atrophy in cocaine use disorder.BMC medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Transcranial Magnetic Stimulation (TMS) is rapidly developing as a therapeutic tool for multiple psychiatric disorders. All current FDA-cleared TMS indications for psychiatric illness target the frontal lobes. Historically, TMS target selection was based on reports of brain lesion locations that cause illness or functional neuroimaging correlates within the prefrontal cortex. In addition to prefrontal targets, however, these neuroimaging studies have also consistently implicated posterior brain regions in a variety of psychiatric disorders. To date, these posterior regions have rarely been tested in TMS clinical trials. In this perspective, we consider the role of posterior regions in psychiatric disorders such as the occipital cortex, precuneus, inferior parietal lobules (IPL), and cerebellum. We synthesize preliminary evidence across few existing TMS trials targeting posterior regions and consider the risks and benefits of stimulating posterior targets for the treatment of psychiatric illness.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.